|Mr. Gary S. Gillheeney Sr.||Pres, CEO & Director||1.61M||N/A||1955|
|Mr. David C. Francisco||Chief Financial Officer||553.19k||N/A||1966|
|Mr. Patrick Bilbo||Chief Operating Officer||741.46k||N/A||1962|
|Ms. Lori H. Freedman B.A., Esq., J.D.||VP & Gen. Counsel||N/A||N/A||1967|
|Mr. Kurt Matheson||VP of Marketing||N/A||N/A||N/A|
|Mr. Thomas L. Pearl||VP of HR||N/A||N/A||N/A|
|Dr. Zorina Pitkin||Sr. VP of Quality Systems||N/A||N/A||N/A|
|Mr. Brian Grow||Chief Commercial Officer||N/A||N/A||1976|
|Mr. Henry Hagopian III||Sr. VP of Fin. & Treasurer||N/A||N/A||1968|
|Mr. William R. Kolb CPA||Sec.||N/A||N/A||N/A|
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Organogenesis Holdings Inc.’s ISS governance QualityScore as of 31 July 2022 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 4; Compensation: 6.